Cardio Flow, founded in Saint Paul, United States, is an early-stage development company dedicated to revolutionizing the treatment of peripheral artery disease (PAD) through its innovative approach to orbital atherectomy. The company's core mission is to improve patient outcomes by providing advanced medical devices that offer a safer and more effective method for removing arterial plaque. Cardio Flow's flagship product, the FreedomFlow platform, is designed for use by physicians and clinics to enhance the debulking process in PAD treatments.
Notable figures associated with Cardio Flow include leading medical professionals and experienced industry investors who support its mission. The company has achieved significant milestones, including successful clinical trials such as FAST I and FAST II, which have demonstrated the effectiveness of the FreedomFlow platform. Cardio Flow's impact lies in its potential to transform the standard of care for PAD patients, offering a promising alternative to existing atherectomy techniques and improving overall vascular health outcomes.
